Interacciones de Lemborexant

Intervention: Avoid alcohol consumption with DAYVIGO [see Warnings and Precautions ( 5.1 )]. (etiqueta de Lemborexant, Interacciones medicamentosas)

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (etiqueta de Alprazolam, Advertencias y precauciones)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (etiqueta de Azelastina y fluticasona, Advertencias y precauciones)

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (etiqueta de Belladona y opio, Advertencia en recuadro)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Buprenorfina, Advertencia en recuadro)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Advertencia en recuadro)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Butalbital, paracetamol, cafeína y codeína, Advertencia en recuadro)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Butorfanol, Advertencia en recuadro)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (etiqueta de Carbinoxamina, Advertencias y precauciones)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (etiqueta de Cetirizina, Advertencias y precauciones)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (etiqueta de Ciclobenzaprina, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (etiqueta de Ciprofloxacino, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etiqueta de Clonazepam, Advertencias)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (etiqueta de Clonidina, Advertencias y precauciones)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etiqueta de Clorazepato, Advertencias)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etiqueta de Clordiazepóxido, Advertencias)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etiqueta de Clordiazepóxido y clidinio, Advertencias)

…have a breathing problem such as emphysema or chronic bronchitis glaucoma trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers When using this product excitability may occur, especially in children drowsiness may occur avoid alcoholic beverages alchohol, sedatives and tranquilizers… (etiqueta de Clorfenamina, Advertencias)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). (etiqueta de Clorpromazina, Contraindicaciones)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Codeína, Advertencia en recuadro)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etiqueta de Diazepam, Advertencias)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (etiqueta de Difenoxilato y atropina, Contraindicaciones)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

…breathing problem such as emphysema or chronic bronchitis • glaucoma • trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking • a sedative or any other sleep-aid • tranquilizers • any other antihistamines • any other drugs When using this product • avoid alcoholic beverages • do not drive a motor vehicle or operate… (etiqueta de Doxilamina, Advertencias)

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (etiqueta de Doxilamina y piridoxina, Advertencias y precauciones)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (etiqueta de Eszopiclona, Advertencias y precauciones)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (etiqueta de Fenelzina, Contraindicaciones)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Fentanilo, Advertencia en recuadro)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

CONTRAINDICATIONS Phenothiazines are contraindicated in patients with suspected or established subcortical brain damage, in patients receiving large doses of hypnotics, and in comatose or severely depressed states. (etiqueta de Flufenazina, Contraindicaciones)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (etiqueta de Gabapentina, Advertencias y precauciones)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Hidrocodona, Advertencia en recuadro)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (etiqueta de Hidrocodona e ibuprofeno, Advertencia en recuadro)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (etiqueta de Hidrocodona y clorfenamina, Advertencia en recuadro)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (etiqueta de Hidrocodona y homatropina, Advertencia en recuadro)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Hidrocodona y paracetamol, Advertencia en recuadro)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (etiqueta de Hidromorfona, Advertencia en recuadro)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (etiqueta de Hidroxizina, Precauciones)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (etiqueta de Ketamina, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (etiqueta de Levocetirizina, Advertencias y precauciones)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Levorfanol, Advertencia en recuadro)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (etiqueta de Lorazepam, Advertencias y precauciones)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (etiqueta de Metadona, Advertencia en recuadro)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (etiqueta de Metaxalona, Advertencias y precauciones)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (etiqueta de Midazolam, Advertencia en recuadro)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Morfina, Advertencia en recuadro)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Nalbufina, Advertencia en recuadro)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (etiqueta de Nalmefeno, Advertencias y precauciones)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Oliceridina, Advertencia en recuadro)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (etiqueta de Olopatadina, Advertencias y precauciones)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (etiqueta de Olopatadina y mometasona, Advertencias y precauciones)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etiqueta de Oxazepam, Advertencias)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (etiqueta de Oxibato de sodio, Advertencia en recuadro)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Oxicodona, Advertencia en recuadro)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (etiqueta de Oxicodona y paracetamol, Advertencia en recuadro)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Oximorfona, Advertencia en recuadro)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Paracetamol y codeína, Advertencia en recuadro)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (etiqueta de Pentazocina y naloxona, Advertencia en recuadro)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

CONTRAINDICATIONS Perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown… (etiqueta de Perfenazina, Contraindicaciones)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Petidina (meperidina), Advertencia en recuadro)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (etiqueta de Pregabalina, Advertencias y precauciones)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). Do not use in pediatric surgery. (etiqueta de Proclorperazina, Contraindicaciones)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (etiqueta de Prometazina y codeína, Advertencia en recuadro)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Remifentanilo, Advertencia en recuadro)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Tapentadol, Advertencia en recuadro)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inducers: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Tramadol, Advertencia en recuadro)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (etiqueta de Tramadol y paracetamol, Advertencia en recuadro)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (etiqueta de Triazolam, Advertencias y precauciones)

CONTRAINDICATIONS A known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and preexisting liver damage. (etiqueta de Trifluoperazina, Contraindicaciones)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (etiqueta de Lemborexant, Interacciones medicamentosas)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (etiqueta de Zaleplón, Advertencias)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (etiqueta de Zolpidem, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (etiqueta de Alopurinol, Advertencias y precauciones)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (etiqueta de Aminofilina, Interacciones medicamentosas)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Use with CNS depressants may result in an additive or potentiating effect. (etiqueta de Brimonidina, Interacciones medicamentosas)

Use with CNS depressants may result in an additive or potentiating effect. (etiqueta de Brimonidina y timolol, Interacciones medicamentosas)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etiqueta de Bupivacaína, Advertencias y precauciones)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etiqueta de Bupivacaína y adrenalina, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (etiqueta de Buspirona, Interacciones medicamentosas)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Examples: Strong CYP3A inhibitors: itraconazole, clarithromycin Moderate CYP3A inhibitors: fluconazole, verapamil Weak CYP3A inhibitors: chlorzoxazone, ranitidine Strong and Moderate CYP3A Inducers Clinical Impact: Concomitant use with a strong or moderate CYP3A inducer decreases lemborexant exposure, which may reduce DAYVIGO efficacy [see Clinical Pharmacology… (etiqueta de Lemborexant, Interacciones medicamentosas)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (etiqueta de Deutetrabenazina, Interacciones medicamentosas)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etiqueta de Lidocaína y adrenalina, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (etiqueta de Metirosina, Interacciones medicamentosas)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (etiqueta de Naloxona, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Examples: Strong CYP3A inhibitors: itraconazole, clarithromycin Moderate CYP3A inhibitors: fluconazole, verapamil Weak CYP3A inhibitors: chlorzoxazone, ranitidine Strong and Moderate CYP3A Inducers Clinical Impact: Concomitant use with a strong or moderate CYP3A inducer decreases lemborexant exposure, which may reduce DAYVIGO efficacy [see Clinical Pharmacology… (etiqueta de Lemborexant, Interacciones medicamentosas)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (etiqueta de Teofilina, Interacciones medicamentosas)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (etiqueta de Trihexifenidilo, Interacciones medicamentosas)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (etiqueta de Trimetobenzamida, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (etiqueta de Lemborexant, Advertencias y precauciones)

Risk increases with dose and use with other central nervous system (CNS) depressants. (etiqueta de Lemborexant, Advertencias y precauciones)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (etiqueta de Dexanfetamina, Interacciones medicamentosas)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (etiqueta de Doxapram, Advertencias)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (etiqueta de Prazosina, Interacciones medicamentosas)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (etiqueta de Montelukast, Interacciones medicamentosas)